Pfizer, BioNTech dose first U.S. patients in Covid-19 vaccine trial | MedCity |

The Phase I/II study dosed its first cohort in Germany last week. The trial is enrolling 7,600 participants who will be randomized to receive one of four vaccine candidates or placebo.

...
The trial is designed to determine safety, immunogenicity and optimal dose of four vaccine candidates. The study, of which BioNTech is the main sponsor, is enrolling 7,600 participants and randomizing them to receive one of four vaccine candidates - BNT162a1, BNT162b1, BNT162b2 and BNT162c2 - or placebo. The companies said the two medical schools are dosing participants, though the ClinicalTrials.gov page for the study, last updated Tuesday, still listed NYU Langone Health as not yet recruiting as of midday, while two other University of Maryland sites were also listed as not yet recruiting. The announcement stated that two additional sites not listed on the trial page - the University of Rochester in upstate New York and Cincinnati Children's Hospital Medical Center - would begin enrollment shortly.

My earlier post ...

Global Reach Partnership Pfizer and German BioNTech